<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04158674</url>
  </required_header>
  <id_info>
    <org_study_id>ELLOUZE_ORION_2018</org_study_id>
    <nct_id>NCT04158674</nct_id>
  </id_info>
  <brief_title>Interest of Levosimendan in Reducing Weaning Failures of ExtraCorporeal Life Support - ECLS</brief_title>
  <acronym>Weanilevo</acronym>
  <official_title>Interest of Levosimendan in Reducing Weaning Failures of ExtraCorporeal Life Support - ECLS. Randomized, Controlled, Multicenter, Double-blind, Multicenter Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Extracorporeal life support (ECLS) is a circulatory cardio supplementation technique; it&#xD;
      therefore makes it possible to compensate for a defective cardiac or cardio-respiratory&#xD;
      function. ECLS nevertheless remains a temporary assistance technique pending a potential&#xD;
      recovery of cardiac function, or it can be used to direct patients towards a heart transplant&#xD;
      or long-term circulatory assistance (Left Ventricular Assist Device (LVAD) or Total Heart).&#xD;
      In patients with complete or partial recovery of cardiac and circulatory function, ECLS&#xD;
      withdrawal may be considered. Withdrawal from ECLS remains a delicate phase and the risk of&#xD;
      failure is high. The mechanism of action of levosimendan, a drug that increases the&#xD;
      contractility of the heart, suggests that it would improve the heart-vessel connection and&#xD;
      reduce the rate of ECLS withdrawal failure. The effect of levosimendan is maximal 24 to 48&#xD;
      hours after the end of the infusion and has a prolonged period of action.&#xD;
&#xD;
      The objective is to evaluate the efficacy of levosimendan administration (0.2 µg/kg/min over&#xD;
      24 hours) - versus placebo - prior to ECLS removal on the rate of withdrawal failure in&#xD;
      patients under ECLS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 24, 2020</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ECLS withdrawal failure</measure>
    <time_frame>7 days after ECLS removal</time_frame>
    <description>Withdrawal failure is defined as the absence of ECLS discontinuation within 48 hours of randomization or the use of temporary circulatory assistance such as ECLS, Impella® pump or intra-aortic balloon pump (IABP) or death</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Acute Decompensated Heart Failure</condition>
  <arm_group>
    <arm_group_label>Levosimendan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levosimendan</intervention_name>
    <description>Levosimendan 2.5mg/ml, solution to be diluted for infusion Dilution in a 500ml bag of 5% Glucose The product is administered as a continuous infusion for 24 hours at an initial rate of 0.2 µg/kg/min</description>
    <arm_group_label>Levosimendan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cernevit</intervention_name>
    <description>mixture of 12 vitamins The dilution of the treatment is done in a 500ml bag of 5% Glucose The product is administered as a continuous infusion for 24 hours at an initial rate of 0.2 µg/kg/min</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  adult patient&#xD;
&#xD;
          -  patient or person responsible for the patient has given written consent&#xD;
&#xD;
          -  patient with acute circulatory heart failure under ECLS&#xD;
&#xD;
          -  patient meeting criteria for ECLS withdrawal&#xD;
&#xD;
               -  ECLS flow rate at 1.0-1.5l/min and/or ECLS pump rpm ≤ 1500 rpm&#xD;
&#xD;
               -  LVEF &gt; 20% in cardiac ultrasound and aortic ITV &gt; 10 cm&#xD;
&#xD;
               -  VIS score ≤ 10&#xD;
&#xD;
               -  Arterial lactates ≤ 2 mmol/l&#xD;
&#xD;
               -  Right ventricular outflow tract shortening fraction &gt; 30%&#xD;
&#xD;
               -  Basal diameter at the tricuspid telediastolic ring of the right ventricle &lt; 35 mm&#xD;
&#xD;
               -  Fraction of inspired oxygen combined between ventilator and ECLS &lt; 80%&#xD;
&#xD;
          -  ECLS withdrawl scheduled within 48 hours&#xD;
&#xD;
          -  Absence of an initial or progressive infectious episode (no planned introduction of&#xD;
             antibiotic therapy within 48 hours prior to inclusion)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with hepatic insufficiency: cytolysis at least 20 times normal&#xD;
&#xD;
          -  Drug intoxication and attempted suicide&#xD;
&#xD;
          -  Patient with a contraindication to the use of levosimendan:&#xD;
&#xD;
               -  hypersensitivity to the active substance or any of the excipients&#xD;
&#xD;
               -  severe hypotension and ventricular tachycardia&#xD;
&#xD;
               -  significant mechanical obstructions affecting ventricular filling and/or ejection&#xD;
&#xD;
               -  severe renal failure (creatinine clearance &lt; 30 ml/min)&#xD;
&#xD;
               -  severe liver failure (TP&lt;50%)&#xD;
&#xD;
               -  history of torsades de pointes&#xD;
&#xD;
          -  Patient with a contraindication to the use of CERNEVIT®:&#xD;
&#xD;
               -  hypersensitivity to active substances, in particular to vitamin B1 or to one of&#xD;
                  the excipients or to soy protein products or to peanut protein products&#xD;
&#xD;
               -  hypervitaminosis to any vitamin contained in this formulation&#xD;
&#xD;
               -  severe hypercalcemia, hyper calciuria, tumour, bone metastasis, primary&#xD;
                  hyperparathyroidism, granulomatosis&#xD;
&#xD;
          -  patient not affiliated to or not benefiting from national health insurance&#xD;
&#xD;
          -  patient subject to legal protection (curatorship, guardianship)&#xD;
&#xD;
          -  patient subject to limited judicial protection&#xD;
&#xD;
          -  pregnant, parturient or breastfeeding woman&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mohamed Omar ELLOUZE</last_name>
    <phone>03.80.29.32.62</phone>
    <phone_ext>+33</phone_ext>
    <email>mohamedomar.ellouze@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Dijon Bourgogne</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed Omar ELLOUZE</last_name>
      <phone>03 80 29 32 62</phone>
      <phone_ext>+33</phone_ext>
      <email>mohamedomar.ellouze@chu-dijon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>November 7, 2019</study_first_submitted>
  <study_first_submitted_qc>November 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2019</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simendan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

